Ambiotis is very proud to have actively participated with OSE Immunotherapeutics to the development of an antibody that targets resolution of inflammation pathways. ChemR23 is a GPCR targeted by Resolvin E1. OSE-230 is an anti-ChemR23 agonist antibody that have been shown to promote efferocytosis (clearance of dead cells by macrophages) and reduce apoptosis of neutrophils; major hallmarks of inflammation resolution. It also triggered resolution in chronic colitis model with beneficial impact on tissue lesions, fibrosis and inflammation-driven tumors. This is a first-in-class drug dealing with pro-resolutive properties.
Check the publication here :“Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation”.
The Ambiotis news
- Details
- Details
A good inflammation resolution is associated with a correct healing and tissue repair. Ambiotis has recently developed new approaches in the area of healing, remodeling and regeneration. Our scratch assay allows the accurate evaluation of compound capacity to accelerate healing. It can be combined with biochemical analysis of lipids or cytokines. Our model of fibroblasts in co-culture with macrophages is perfectly suitable to observe the impact of compounds on the switch from pro-inflammatory to regenerative macrophages, the production of lipids involved in healing process (MCTR) and the remodeling of the extracellular matrix.
- Details
How do tissues fight against infection and regenerate?
Inflammation resolution may indeed be involved in these fascinating biological processes through the action of the SPMs (Specialized Pro-resolving Mediators).
In this recent publication, Chiang et al. identified genes and pathways that might link resolution of inflammation and regeneration using planaria model. They showed how tissue regeneration is regulated by cys-SPMs pathways, and in particular by TRAF3. TRAF3 indeed contributes to cys-SPM–stimulated phagocyte functions and resolution of infection.
Here you can find more information about this study : click here